# Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis

> **NCT03293173** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Nordic Lymphoma Group** · enrollment: 120 (estimated)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **COMBINATION_PRODUCT:** R-CHOEP
- **COMBINATION_PRODUCT:** DA-EPOCH-R

## Key facts

- **NCT ID:** NCT03293173
- **Lead sponsor:** Nordic Lymphoma Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-08-04
- **Primary completion:** 2021-01-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-06-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03293173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03293173, "Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT03293173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*